Celera Launches into Drug Target Sector | GenomeWeb

SAN FRANCISCO, Jan 10 – Celera Genomics on Wednesday announced moves that signal the beginning of the company's foray into the drug target discovery sector.

"We are looking to identify new drug targets," Peter Chambre, Celera’s chief operating officer, said at a company presentation at the JP Morgan H&Q conference.

As part of that move, Celera also announced on Wednesday that it had hired Stephen Hoffman, a pioneer in the development of DNA vaccines, as its senior vice president of immunotherapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.